denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Hematology Disease Topics & Pathways:
GVHD, Diseases, Immune Disorders
Description:
Prevention remains the cornerstone of graft versus host disease (GVHD) management. The landscape of GVHD prevention is undergoing significant changes, with modifications to the standard calcineurin inhibitor and methotrexate regimens, along with incorporation of novel agents, and development of innovative graft manipulation techniques. These advancements have expanded donor pool, including the use of haploidentical and mismatched unrelated donors. However, despite these improvements, GVHD continues to be a major cause of morbidity and mortality after transplantation. Biomarker algorithms show promise in developing preemptive approaches to reduce GVHD and improve GVHD treatment outcomes.
In this review Dr. Schultz will summarize the state-of-the-art risk assignments and algorithms for acute and chronic GVHD and discuss current approaches and limitations for preemptive therapy.
Dr. Qayed will review recent clinical trials and approaches to acute GVHD prophylaxis, including in unrelated and haploidentical donor transplantation, and discuss changes in clinical practice as well as emerging strategies and ongoing clinical trials.
Dr. Amanam will review clinical trial results regarding chronic GVHD outcomes, promising targeted agents for chronic GVHD treatment, and the use of novel endpoints to assess the effectiveness of GVHD-directed therapies.
In this review Dr. Schultz will summarize the state-of-the-art risk assignments and algorithms for acute and chronic GVHD and discuss current approaches and limitations for preemptive therapy.
Dr. Qayed will review recent clinical trials and approaches to acute GVHD prophylaxis, including in unrelated and haploidentical donor transplantation, and discuss changes in clinical practice as well as emerging strategies and ongoing clinical trials.
Dr. Amanam will review clinical trial results regarding chronic GVHD outcomes, promising targeted agents for chronic GVHD treatment, and the use of novel endpoints to assess the effectiveness of GVHD-directed therapies.